Avalo Therapeutics, Inc. (AVTX) is a publicly traded company in the Unknown sector. Across all available filings, 13 corporate insiders have executed 76 transactions totaling $18.8M, demonstrating a bullish sentiment with $14.2M in net insider flow. The most recent transaction on Dec 10, 2025 involved a transaction of 155 shares valued at $636.
No significant insider buying has been recorded for AVTX in the recent period.
No significant insider selling has been recorded for AVTX in the recent period.
Based on recent SEC filings, insider sentiment for AVTX is bullish with an Insider Alignment Score of 88/100 and a net flow of $14.2M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Avalo Therapeutics, Inc. (AVTX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 13 insiders are actively trading AVTX stock, having executed 76 transactions in the past 90 days. The most active insider is Capital, Llc Armistice (Executive), who has made 11 transactions totaling $13.0M.
Get notified when executives and directors at AVTX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | Ryan Sullivan Christopher | Executive | Payment | 155 | $4.10 | $636 | |
| Dec 10, 2025 | Varki Paul | Executive | Payment | 1,016 | $4.10 | $4.2K | |
| Dec 10, 2025 | Riley Jennifer | Executive | Payment | 637 | $4.10 | $2.6K | |
| Dec 10, 2025 | Doyle Mittie | Executive | Payment | 1,013 | $4.10 | $4.2K | |
| Nov 14, 2025 | Goldman Jonathan | Executive | Sale | 3,167 | $14.30 | $45.3K | |
| Nov 14, 2025 | Goldman Jonathan | Executive | Option Exercise | 8,200 | $9.88 | $81.0K | |
| Nov 14, 2025 | Goldman Jonathan | Executive | Sale | 8,200 | $14.35 | $117.7K | |
| Jun 27, 2023 | Master Fund Ltd. Armistice Capital | Executive | Sale | 937,404 | $0.52 | $487.5K | |
| Jun 26, 2023 | Management Ltd. Caissa Capital | Executive | Purchase | 182,300 | $0.62 | $113.0K | |
| Jun 26, 2023 | Management Ltd. Caissa Capital | Executive | Purchase | 1,425,700 | $0.64 | $912.4K | Large |
| Jun 26, 2023 | Master Fund Ltd. Armistice Capital | Executive | Sale | 2,746,138 | $0.61 | $1.7M | Large |
| Jun 20, 2023 | Management Ltd. Caissa Capital | Executive | Purchase | 2,000 | $4.14 | $8.3K | |
| Jun 16, 2023 | Management Ltd. Caissa Capital | Executive | Purchase | 3,000 | $3.90 | $11.7K | |
| Jun 15, 2023 | Management Ltd. Caissa Capital | Executive | Purchase | 3,160 | $3.68 | $11.6K | |
| Jun 14, 2023 | Management Ltd. Caissa Capital | Executive | Purchase | 6,000 | $3.48 | $20.9K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 66 | $16.5M | 87.2% |
Sale(S) | 4 | $2.3M | 12.3% |
Exercise(M) | 1 | $81.0K | 0.4% |
Payment(F) | 4 | $11.6K | 0.1% |
Small Acquisition(L) | 1 | $1.3K | 0.0% |
Insiders at Avalo Therapeutics, Inc. are accumulating shares at an accelerated pace. With 13 insiders making 76 transactions totaling $16.5M in purchases versus $2.3M in sales, the net buying activity of $14.2M signals strong executive confidence. Capital, Llc Armistice (Executive) leads the buying activity with $13.0M in transactions across all time.